These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 25310214)

  • 1. Langerhans cell histiocytosis.
    Grana N
    Cancer Control; 2014 Oct; 21(4):328-34. PubMed ID: 25310214
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
    Abla O; Weitzman S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Langerhans cell histiocytosis of the temporal bone: A review of 29 cases at a single center.
    Modest MC; Garcia JJ; Arndt CS; Carlson ML
    Laryngoscope; 2016 Aug; 126(8):1899-904. PubMed ID: 26535795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating skin-limited and multisystem Langerhans cell histiocytosis.
    Simko SJ; Garmezy B; Abhyankar H; Lupo PJ; Chakraborty R; Lim KP; Shih A; Hicks MJ; Wright TS; Levy ML; McClain KL; Allen CE
    J Pediatr; 2014 Nov; 165(5):990-6. PubMed ID: 25441388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome and prognosis of mixed histiocytosis (Erdheim-Chester disease and Langerhans Cell Histiocytosis).
    Pegoraro F; Papo M; Cohen-Aubart F; Peyronel F; Lugli G; Trambusti I; Baulier G; de Menthon M; Le Scornet T; Oziol E; Ferreira-Maldent N; Hermine O; Faucher B; Koschel D; Straetmans N; Abisror N; Terrier B; Lifermann F; Razanamahery J; Allenbach Y; Keraen J; Bulifon S; Hervier B; Buccoliero A; Charlotte F; Monzani Q; Boussouar S; Shor N; Tondo A; Barete S; Idbaih A; Tazi A; Sieni E; Amoura Z; Emile JF; Vaglio A; Haroche J
    EClinicalMedicine; 2024 Jul; 73():102658. PubMed ID: 38841707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
    Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
    Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis.
    Varga E; Korom I; Polyánka H; Szabó K; Széll M; Baltás E; Bata-Csörgő Z; Kemény L; Oláh J
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1205-11. PubMed ID: 25351766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of a case of acute myeloid leukemia following Langerhans cell histiocytosis in an adolescent: a case report and review of the literature.
    Xu G; Yang M; Huang J; Jin J
    Int J Clin Exp Med; 2015; 8(2):3024-6. PubMed ID: 25932277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
    Kemps PG; Zondag TCE; Arnardóttir HB; Solleveld-Westerink N; Borst J; Steenwijk EC; van Egmond D; Swennenhuis JF; Stelloo E; Trambusti I; Verdijk RM; van Noesel CJM; Cleven AHG; Scheijde-Vermeulen MA; Koudijs MJ; Krsková L; Hawkins C; Egeler RM; Brok J; von Bahr Greenwood T; Svojgr K; Beishuizen A; van Laar JAM; Pötschger U; Hutter C; Sieni E; Minkov M; Abla O; van Wezel T; van den Bos C; van Halteren AGS
    Blood Adv; 2023 Feb; 7(4):664-679. PubMed ID: 36083130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Langerhans cell histiocytosis in adults].
    Néel A; Artifoni M; Donadieu J; Lorillon G; Hamidou M; Tazi A
    Rev Med Interne; 2015 Oct; 36(10):658-67. PubMed ID: 26150351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical cellular disorders.
    McClain KL; Natkunam Y; Swerdlow SH
    Hematology Am Soc Hematol Educ Program; 2004; ():283-96. PubMed ID: 15561688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.
    Wang D; Chen XH; Wei A; Zhou CJ; Zhang X; Ma HH; Lian HY; Zhang L; Zhang Q; Huang XT; Wang CJ; Yang Y; Liu W; Wang TY; Li ZG; Cui L; Zhang R
    Orphanet J Rare Dis; 2022 Apr; 17(1):151. PubMed ID: 35379272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
    Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
    Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Risk Model Composed of Complete Blood Count,
    Wang L; Yuan L; Du X; Zhou K; Yang Y; Qin Q; Yang L; Xiang Y; Qu X; Liu H; Qin X; Liu C
    Front Oncol; 2022; 12():800786. PubMed ID: 35186740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic Alterations in Langerhans Cell Histiocytosis.
    Rollins BJ
    Hematol Oncol Clin North Am; 2015 Oct; 29(5):839-51. PubMed ID: 26461146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated Langerhans cell histiocytosis of the sublingual gland in an adult.
    Yang S; Chen X; Zhang J; Fang Q
    Int J Clin Exp Pathol; 2015; 8(10):13647-50. PubMed ID: 26722591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.